Amedisys Inc (NASDAQ:AMED) Director Bruce D. Perkins purchased 2,500 shares of Amedisys stock in a transaction on Wednesday, May 15th. The stock was bought at an average cost of $111.84 per share, for a total transaction of $279,600.00. Following the transaction, the director now directly owns 22,088 shares in the company, valued at $2,470,321.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of AMED traded down $3.89 during mid-day trading on Friday, reaching $108.34. The company’s stock had a trading volume of 456,200 shares, compared to its average volume of 469,627. Amedisys Inc has a 12-month low of $71.74 and a 12-month high of $140.91. The company has a market cap of $3.55 billion, a P/E ratio of 29.85, a PEG ratio of 1.38 and a beta of 1.33. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.91 and a current ratio of 0.91.
Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Tuesday, April 30th. The health services provider reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.22. Amedisys had a return on equity of 28.25% and a net margin of 7.14%. The business had revenue of $467.34 million for the quarter, compared to the consensus estimate of $460.83 million. During the same quarter in the prior year, the business posted $0.79 EPS. The business’s revenue for the quarter was up 17.0% on a year-over-year basis. As a group, analysts predict that Amedisys Inc will post 4.08 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY increased its holdings in shares of Amedisys by 85.9% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 16,183 shares of the health services provider’s stock valued at $1,994,000 after acquiring an additional 7,480 shares during the last quarter. FMR LLC increased its holdings in shares of Amedisys by 13.4% in the 1st quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock valued at $45,703,000 after acquiring an additional 43,844 shares during the last quarter. Kiwi Wealth Investments Limited Partnership increased its holdings in shares of Amedisys by 13.9% in the 1st quarter. Kiwi Wealth Investments Limited Partnership now owns 32,001 shares of the health services provider’s stock valued at $3,944,000 after acquiring an additional 3,895 shares during the last quarter. BlueCrest Capital Management Ltd purchased a new position in shares of Amedisys in the 1st quarter valued at about $364,000. Finally, Zebra Capital Management LLC increased its holdings in shares of Amedisys by 8.0% in the 1st quarter. Zebra Capital Management LLC now owns 9,102 shares of the health services provider’s stock valued at $1,122,000 after acquiring an additional 672 shares during the last quarter. Institutional investors and hedge funds own 91.71% of the company’s stock.
A number of equities research analysts have issued reports on AMED shares. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 28th. Barclays increased their price target on Amedisys from $115.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, March 21st. Zacks Investment Research lowered Amedisys from a “buy” rating to a “hold” rating in a research report on Monday, January 21st. Raymond James raised Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 price target on the stock in a research report on Thursday, May 2nd. Finally, Craig Hallum reduced their price target on Amedisys from $132.00 to $124.00 and set a “hold” rating on the stock in a research report on Friday, March 1st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. Amedisys has a consensus rating of “Hold” and a consensus price target of $125.90.
WARNING: “Insider Buying: Amedisys Inc (AMED) Director Purchases 2,500 Shares of Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2019/05/17/insider-buying-amedisys-inc-amed-director-purchases-2500-shares-of-stock.html.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Article: What does a bar chart display?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.